A landmark analysis in The New England Journal of Medicine challenges clinicians to reconsider using racial categories as a basis for medication dosing decisions. Researchers argue that current race-based dosing recommendations lack adequate scientific evidence and may inadvertently perpetuate health disparities rather than improve patient outcomes.
The perspective emphasizes that racial categories serve as imprecise proxies for the complex interplay of genetic, environmental, and social factors that actually influence how patients metabolize medications. Instead, the analysis advocates for precision medicine approaches that utilize pharmacogenetic testing and specific biomarkers to guide treatment decisions.
This evidence-based critique signals a potential shift in clinical guidelines, encouraging healthcare providers to move toward individualized dosing strategies that better account for each patient’s unique pharmacokinetic profile. Such approaches promise both improved efficacy and greater equity in medical care.
Read the full article on GMJ Newsroom.
Was this article helpful?
